References
- World Health Organization. WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19 - 11 March 2020. [cited 2022 Mar 18]; Available from www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19–-11-march-2020.
- Polack FP, Thomas SJ, Kitchin N, C4591001 Clinical Trial Group, et al. Safety and efficacy of the BNT162b2 covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
- Baden LR, El Sahly HM, Essink B, COVE Study Group, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 ;384(5):403–416.
- Sadoff J, Glenda G, Vandebosch A, ENSEMBLE Study Group, et al. Safety and efficacy of Single-Dose Ad26.COV2.S vaccine against covid-19. N Engl J Med. 2021;384(23):2187–2201.
- Cairns R, Buckley NA. The poisoning severity score: if it did not exist, We would have to invent it. J Med Toxicol. 2017;13(2):131–134.
- Cai C, Peng Y, Shen E, et al. A comprehensive analysis of the efficacy and safety of COVID-19 vaccines. Mol Ther. 2021 ;29(9):2794–2805.
- Spyker DA, Bronstein AC, Weber JA. Making US poison centers a part of the solution to the COVID-19 pandemic. Clin Toxicol (Phila). 2022; 60(1):102–114.
- Shay DK, Gee J, Su JR, et al. Safety monitoring of the janssen (johnson & johnson) COVID-19 Vaccine - United States, March-April 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(18):680–684.
- Gargano J, Wallace M, Hadler S, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization Practices - United States, june 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(27):977–982.
- Albalawi O, Alomran M, Alsagri G, et al. Analyzing the U.S. Post-marketing safety surveillance of COVID-19 vaccines. Saudi Pharm J. 2022;30(2):180–184.
- Himmelstein M, Sanchez D. Masculinity impediments: internalized masculinity contributes to healthcare avoidance in men and women. J Health Psychol. 2016;21(7):1283–1292.